This was not the case for wild-type EGFR, suggesting that PD-L1 expression is increased by EGFR signaling conferred by activating EGFR mutations (17) and the promotion of immune escape in lung cancer via increased PD-L1 expression through resistance to EGFR-directed small tyrosine kinase inhibitors (53). The gene discussed is EGFR; the disease is lung cancer.